% Financial costs in 2019 amounted to THB 34 million, an increase of 25.6% from last year regarding to TBSP consolidation and extra finance cost from additional long- term loan for Tender Offer in TBSP
) Consolidation goodwill 439 418 4.9 Property, plant and equipment 12,730 11,601 9.7 Other assets 1,970 1,097 79.7 Tota Assets 55,776 45,958 21.4 Trade and other payables 15,371 10,151 51.4 Liabilities and
354 (96.0) Other current assets 1658 1,563 6.1 Property, plant and equipment 14,069 12,724 10.6 Right-of-use assets 380 377 0.9 Consolidation goodwill 436 437 (0.2) Other assets 1,184 1,229 (3.7) Tota
(5.0) Current investments 865 2 50,825.8 Trade and other receivables 11,162 9,739 14.6 Inventories 9,719 8,963 8.4 Investments in associated companies 423 464 (9.0) Consolidation goodwill 431 418 3.2
ที่มีอำนาจลงนาม (signer)1 ในการ https://publish.sec.or.th/nrs/9584a19.pdf 17063049.pdf an otherwise good seasonal quarter, and taken together with de-consolidation of India PET business, had a volume
% 51.41 63.64% 4. Livestock 11.47 3.62% 9.27 2.50% (2.20) (19.18%) Total Sales revenues 316.83 100.00% 371.33 100.00% 54.50 17.20% Such growth was driven by a surge in revenues from sales of companion
www.interpharma.co.th Inter Pharma Co. Ltd. 140/9 ITF Tower, 9th Floor, Silom Road, Suriyawong, Bangrak, Bangkok 10500, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th a surge in revenues from sales of
administrative expenses for the three months period ended 31 March 2018 and 2019 at THB 34.11 million and THB 40.14 million respectively. This equals to a surge of 17.68 % in administrative expenses year on year
& expenses (net of tax) from the comparing quarters, the normalized net profit would be approximately THB 72.8 million in 2Q19 comparing to THB 52.4 million in 2Q18 or a surge of 39% . Statement of Financial